In our study to evaluate the diagnostic accuracy of FENO measurement with NioxMino ® for the diagnosis of asthma in general practice, we found the cut-off at FENO £ 12 ppb to rule out mild and moderate to severe asthma with a negative predictive value of 81% (95%CI 64-91%) [1]. We oriented ourselves at the already established value of 12 ppb [2] . However, we overlooked in the ROC analysis that the overall diagnostic accuracy improves slightly when the cut-off is chosen at FENO £ 16 ppb (revised table two) [see table 1]. Negative likelihood ratio was 0.38 (95%CI 0.22-0.64) and positive likelihood ratio was 1.76 (95%CI 1.37-2.26) using the 16 ppb cut-off (revised table three) [see Table 2 ].
Correction
In our study to evaluate the diagnostic accuracy of FENO measurement with NioxMino ® for the diagnosis of asthma in general practice, we found the cut-off at FENO £ 12 ppb to rule out mild and moderate to severe asthma with a negative predictive value of 81% (95%CI 64-91%) [1] . We oriented ourselves at the already established value of 12 ppb [2] . However, we overlooked in the ROC analysis that the overall diagnostic accuracy improves slightly when the cut-off is chosen at FENO £ 16 ppb (revised table  two) [see table 1 ]. Negative likelihood ratio was 0.38 (95%CI 0.22-0.64) and positive likelihood ratio was 1.76 (95%CI 1.37-2.26) using the 16 ppb cut-off (revised table three) [see Table 2 ].
In patients with unsuspicious spirometric results (n = 101; not in table) there was no improvement of diagnostic accuracy. The best cut-off point was at FENO £ 16 ppb again. In this diagnostic group sensitivity was 78% (95%CI 63-89%), specificity was 45% (95%CI 34-57%), PPV was 45% (95%CI 34-57%) and NPV was 78% (95%CI 63-89%). Table 1 below] illustrates that the patient group with correctly excluded asthma by FENO measurement increases at FENO £ 16 ppb; and the range of the confidence interval narrows. Thus three patients need to be diagnosed for excluding asthma in order to save one bronchial provocation test when FENO £ 16 ppb is used as the cut-off point. With FENO £ 12 ppb five patients need to be tested in order to exclude asthma in one of them. Therefore, we suggest choosing FENO £ 16 ppb to rule out mild and moderate to severe asthma. This improves diagnostic efficiency compared to the £ 12 ppb cut-off point.
We would like to correct the following points in the manuscript:
In the Results section of the Abstract lines 6-7 should read as:
"16 ppb (n = 68; 42.5%), sensitivity was 79% (95%CI 67-88), specificity 55% (95%CI 45-64), PPV 50% (95%CI 40-60), NPV 82% (95%CI 72-90)". Also in line 7, "Three" should say "Two".
In the Conclusion section of the Abstract, in line 2, "FENO £ 12 ppb" should say "FENO £ 16 ppb".
In the Sensitivity analyses section, in line 2 of the third paragraph, "FENO £ 12 ppb" should say "FENO £ 16 ppb", "81% (95% CI 64-91)" should say "82% (95% CI 72-90)" and "34" should say "68". In line 3, "FENO £ 12 ppb" should say "FENO £ 16 ppb" and "five" should say "three". In line 4 "12 ppb" should say "16 ppb". The sentence starting in line 5 and ending in line 6 should read: "Sensitivity was 78% (95%CI 63-89), specificity was 45% (95%CI 34-57), PPV was 45% (95%CI 34-57), NPV was 78 (95%CI 63-89)". In line 6, "16 (15.8%)" should say "37 (36.6%)", "FENO £ 12 ppb" should say "FENO £ 16 ppb" and "increased up to 82% (95%CI 64-92)" should say "was 77% (95%CI 61-88)".
In the Discussion section, in line 4, "81%" should say "82%" and in line 5, "FENO £ 12" should say "FENO £ 16"
In the second paragraph, in line 1, "five" should say "three". In line 5, "16 patients had FENO £ 12 ppb" should say "37 patients had FENO £ 16 ppb". Also in line 5, "three" should say "two" and in lines 11 and 12 "FENO £ 12 ppb" should say ""FENO £ 16 ppb" and 12 ppb<FENO should say 16 ppb<FENO.
In the third line of the third paragraph "12 to 46 ppb" should say "16 to 46 ppb" and in the seventh line, the sec- 
